Know Cancer

or
forgot password

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer


N/A
N/A
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer


Inclusion Criteria:



- Patient must have a history of breast cancer.

- Patient must be scheduled to receive standard treatment with Arimidex for adjuvant
hormonal management.

- Patient must be willing to undergo a duct lavage.

- Patient must sign an Informed Consent.

Exclusion Criteria:

- None.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Number of Patients with Antiproliferative Effects of Arimidex

Outcome Description:

Biomarker modulation study on effects of Armimidex in ductal lavage fluid from evaluable epithelial cells specimen.

Outcome Time Frame:

Study duration 4 years

Safety Issue:

No

Principal Investigator

Banu Arun, MD

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

LAB02-0400

NCT ID:

NCT01207635

Start Date:

November 2002

Completion Date:

January 2006

Related Keywords:

  • Breast Cancer
  • Cancer
  • Arimidex
  • Breast Neoplasms

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030